AN2 Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from AN2 Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
AN2 Therapeutics, Inc. made a loss over the last year. AN2 Therapeutics, Inc. owes $0.07 for every $1 it owns. AN2 Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAN2 Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.76The share price is 1.76 times AN2 Therapeutics, Inc.'s book value per share, lower than 62% of Healthcare companies in United States.
Market cap
$134 MThe total market value of all of AN2 Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$76 MWhat AN2 Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.01Net worth divided by the number of shares. The share price of $3.55 is 1.8 times this, which is the P/B above.
Return on equity (ROE)
-50.1%AN2 Therapeutics, Inc. lost 50.1% of its shareholders' money over the last year, lower than 51% of Healthcare companies in United States.
Owes vs Owns
0.07×AN2 Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Dividend yield
NoneAN2 Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossAN2 Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For AN2 Therapeutics, Inc.: $134 M ÷ $76 M (30 Jun 2026) = 1.8.
What is AN2 Therapeutics, Inc.'s return on equity?
AN2 Therapeutics, Inc. lost 50.1% of its shareholders' money over the last year, lower than 51% of Healthcare companies in United States.
How much does AN2 Therapeutics, Inc. owe compared with what it owns?
AN2 Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Does AN2 Therapeutics, Inc. pay a dividend?
No. AN2 Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.